参考文献
［1］Alexander S，Alexander H.Lead genetic studies in Dictyostelium discoideum and translational studies in human cells demonstrate that sphingolipids are key regulators of sensitivity to cisplatin and other anticancer drugs［J］.Semin Cell Dev Biol，2011，22（1）：97-104.
［2］Barakat K，Gajewski M，Tuszynski J A.DNA repair inhibitors：the next major step to improve cancer therapy［J］.Curr Top Med Chem，2012，12（12）：1376-1390.
［3］Borst P，Evers R，Kool M，et al.A family of drug transporters：the multidrug resistance-associated proteins［J］.J Natl Cancer Inst，2000，92（16）：1295-1302.
［4］Kuhlmann M K，Burkhardt G，Köhler H.Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application［J］.Nephrol Dial Transplant，1997，12（12）：2478-2480.
［5］Starha P，Trávníček Z，Popa A，et al.How to modify 7-azaindole to form cytotoxic Pt（Ⅱ）complexes：highly in vitro anticancer effective cisplatin derivatives involving halogenosubstituted 7-azaindole［J］.J Inorg Biochem，2012，115：57-63.
［6］Baruah B，Surin A.Interaction of liposome-encapsulated cisplatin with biomolecules［J］.J Biol Inorg Chem，2012，17（6）：899-910.
［7］Liu H K，Sadler P J.Metal complexes as DNA intercalators［J］.Acc Chem Res，2011，44（5）：349-359.
［8］Pinato O，Musetti C，Farrell N P，et al.Platinum-based drugs and proteins：reactivity and relevance to DNA adduct formation［J］.J Inorg Biochem，2013，122：27-30.
［9］Ramachandran S，Temple B，Alexandrova A N，et al.Recognition of platinum-DNA adducts by HMGB1a［J］.Biochemistry，2012，51（38）：7608-7617.
［10］Cheung-Ong K，Song K T，Ma Z，et al.Comparative chemogenomics to examine the mechanism of action of DNA-targeted platinum-acridine anticancer agents［J］.ACS Chem Biol，2012，7（11）：1892-1901.
［11］Zoppoli G，Regairaz M，Leo E，et al.Putative DNA/RNA helicase Schlafen-11（SLFN11）sensitizes cancer cells to DNA-damaging agents［J］.Proc Natl Acad Sci U S A，2012，109（37）：15030-16035.
［12］Zhang P D，Liu S S，Ngan H Y S.TAp73-mediated the activation of c-Jun N-terminal kinase enhances cellular chemosensitivity to cisplatin in ovarian cancer cells［J］.PLoS One，2012，7（8）：e42985.
［13］Mazumder M E，Beale P，Chan C，et al.Synthesis and cytotoxicity of three trans-palladium complexes containing planaramine ligands in human ovarian tumor models［J］.ChemMedChem，2012，7（10）：1840-1846.
［14］Avital I，Langan R C，Summers T A，et al.Evidencebased guidelines for precision risk stratification-based screening（PRSBS）for colorectal cancer：lessons learned from the US armed forces：consensus and future directions［J］.J Cancer，2013，4（3）：172-192.
［15］Wang Y，Chen L，Huang G C，et al.Klotho sensitizes human lung cancer cell line to cisplatin via PI3k/Akt pathway［J］.PLoS One，2013，8（2）：e57391.
［16］Zhao G Y，Cai C K，Yang T T，et al.MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma［J］.PLoS One，2013，8（1）：e53906.
［17］Girouard J，Lafleur M J，Parent S，et al.Involvement of Akt isoforms in chemoresistance of endometrial carcinoma cells［J］.Gynecol Oncol，2013，128（2）：335-343.
［18］Wyatt L E，Kennedy M J.Cisplatin-induced ototoxicity and the role of pharmacogenetic testing［J］.J Pediatr Pharmacol Ther，2012，17（4）：395-399.
［19］Shin Y S，Song S J，Kang S U，et al.A novel synthetic compound，3-amino-3-（4-fluoro-phenyl）-1H-quinoline-2，4-dione，inhibits cisplatin-induced hearing loss by the suppression of reactive oxygen species：in vitro and in vivo study［J］.Neuroscience，2012，232C：1-12.
［20］Schacht J，Talaska A E，Rybak L P.Cisplatin and aminoglycoside antibiotics：hearing loss and its prevention［J］.Anat Rec（Hoboken），2012，295（11）：1837-1850.
［21］Tanaka F，Whitworth C A，Rybak L P.Round window pH manipulation alters the ototoxicity of systemic cisplatin［J］.Hear Res，2004，187（1-2）：44-50.
［22］Sekikawa A，Fukui H，Zhang X，et al.REG Ⅰ α is a biomarker for predicting response to chemotherapy with S-1 plus cisplatin in patients with unresectable stage Ⅳ gastric cancer［J］.Br J Cancer，2013，108（2）：395-401.
［23］Ryu H G，Jeong S J，Kwon H Y，et al.Penta-O-galloyl-β-D-glucose attenuates cisplatin-induced nephrotoxicity via reactive oxygen species reduction in renal epithelial cells and enhances antitumor activity in Caki-2 renal cancer cells［J］.Toxicol In Vitro，2012，26（2）：206-214.
［24］Lameire N，Kruse V，Rottey S.Nephrotoxicity of anticancer drugs—an underestimated problem？［J］.Acta Clin Belg，2011，66（5）：337-345.
［25］Miller R P，Tadagavadi R K，Ramesh G，et al.Mechanisms of cisplatin nephrotoxicity［J］.Toxins（Basel），2010，2（11）：2490-2518.
［26］Lu H P，Chao C C.Cancer cells acquire resistance to anticancer drugs：an update［J］.Biomed J，2012，35（6）：464-472.
［27］Dille M F，Wilmington D，McMillan G P，et al.Development and validation of a cisplatin dose-ototoxicity model［J］.J Am Acad Audiol，2012，23（7）：510-521.
［28］Topdag M，Iseri M，Gelenli E，et al.Effect of intratympanic dexamethasone，memantine and piracetam on cellular apoptosis due to cisplatin ototoxicity［J］.J Laryngol Otol，2012，126（11）：1091-1096.(https://www.daowen.com)
［29］Park S J，Park S H，Chang J W，et al.Protective effect of klotho protein against cisplatin ototoxicity in an auditory cell line［J］.J Laryngol Otol，2012，126（10）：1003-1009.
［30］Jurajda M，Talach T，Kostřica R，et al.Genetic background of cisplatin induced ototoxicity［J］.Klin Onkol，2012，25（3）：184-187.
［31］Akiyama S，Chen Z S，Sumizawa T，et al.Resistance to cisplatin［J］.Anticancer Drug Des，1999，14（2）：143-514.
［32］Garcia M M，Acquier A，Suarez G，et al.Cisplatin inhibits testosterone synthesis by a mechanism that includes the action of reactive oxygen species（ROS）at the level of P450scc［J］.Chem Biol Interact，2012，199（3）：185-191.
［33］Bryan N，Ahswin H，Smart N，et al.Reactive oxygen species（ROS）—a family of fate deciding molecules pivotal in constructive inflammation and wound healing［J］.Eur Cell Mater，2012，4：249-265.
［34］Addis P，Shecterle L M，St Cyr J A.Cellular protection during oxidative stress：a potential role for D-ribose and antioxidants［J］.J Diet Suppl，2012，9（3）：178-182.
［35］Rybak L P，Whitworth C A，Mukherjea D，et al.Mechanisms of cisplatin-induced ototoxicity and prevention［J］.Hear Res，2007，226（1-2）：157-167.
［36］Bauer G.Tumor cell-protective catalase as a novel target for rational therapeutic approaches based on specific intercellular ROS signaling［J］.Anticancer Res，2012，32（7）：2599-2624.
［37］Hüttemann M，Lee I，Grossman L I，et al.Phosphorylation of mammalian cytochrome c and cytochrome c oxidase in the regulation of cell destiny：respiration，apoptosis，and human disease［J］.Adv Exp Med Biol，2012，748：237-264.
［38］Mellier G，Pervaiz S.The three Rs along the TRAIL：resistance，re-sensitization and reactive oxygen species（ROS）［J］.Free Radic Res，2012，46（8）：996-1003.
［39］Ziech D，Anestopoulos I，Hanafi R，et al.Pleiotrophic effects of natural products in ROS-induced carcinogenesis：the role of plant-derived natural products in oral cancer chemoprevention［J］.Cancer Lett，2012，327（1-2）：16-25.
［40］Ray P D，Huang B W，Tsuji Y.Reactive oxygen species（ROS）homeostasis and redox regulation in cellular signaling［J］.Cell Signal，2012，24（5）：981-990.
［41］Bae Y S，Oh H，Rhee S G，et al.Regulation of reactive oxygen species generation in cell signaling［J］.Mol Cells，2011，32（6）：491-509.
［42］Ghio A J，Carraway M S，Madden M C.Composition of air pollution particles and oxidative stress in cells，tissues，and living systems［J］.J Toxicol Environ Health B Crit Rev，2012，15（1）：1-21.
［43］Shen D W，Pouliot L M，Hall M D，et al.Cisplatin resistance：a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes［J］.Pharmacol Rev，2012，64（3）：706-721.
［44］Dmitriev O Y.Mechanism of tumor resistance to cisplatin mediated by the copper transporter ATP7B［J］.Biochem Cell Biol，2011，89（2）：138-147.
［45］Dhillon K K，Swisher E M，Taniguchi T.Secondary mutations of BRCA1/2 and drug resistance［J］.Cancer Sci，2011，102（4）：663-669.
［46］Li Z Y，Yang Y，Ming M，et al.Mitochondrial ROS generation for regulation of autophagic pathways in cancer［J］.Biochem Biophys Res Commun，2011，414（1）：5-8.
［47］Maines M D.Potential application of biliverdin reductase and its fragments to modulate insulin/IGF-1/MAPK/PI3-K signaling pathways in therapeutic settings［J］.Curr Drug Targets，2010，11（12）：1586-1594.
［48］Bubici C，Papa S，Dean K，et al.Mutual cross-talk between reactive oxygen species and nuclear factor-kappa B：molecular basis and biological significance［J］.Oncogene，2006，25（51）：6731-6748.
［49］Tzivion G，Dobson M，Ramakrishnan G.FoxO transcription factors；regulation by AKT and 14-3-3 proteins［J］.Biochim Biophys Acta，2011，1813（11）：1938-1945.
［50］Berg M，Soreide K.EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer：implications for targeted therapy［J］.Discov Med，2012，14（76）：207-214.
［51］Hemmings B A，Restuccia D F.PI3K-PKB/Akt pathway［J］.Cold Spring Harb Perspect Biol，2012，4（9）：a011189.
［52］Busaidy N L，Farooki A，Dowlati A，et al.Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway［J］.J Clin Oncol，2012，30（23）：2919-2928.
［53］McCubrey J A，Steelman L S，Chappell W H，et al.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors：how mutations can result in therapy resistance and how to overcome resistance［J］.Oncotarget，2012，3（10）：1068-1110.
［54］Ali A Y，Farrand L，Kim J Y，et al.Molecular determinants of ovarian cancer chemoresistance：new insights into an old conundrum［J］.Ann N Y Acad Sci，2012，1271：58-67.
［55］Katoh M，Igarashi M，Fukuda H，et al.Cancer genetics and genomics of human FOX family genes［J］.Cancer Lett，2013，328（2）：198-206.